This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound according to the general Formula (I)



(I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof or ~~and~~ prodrugs thereof, wherein :

n is an integer, equal to ~~0, 1 or 2~~;

m is an integer, equal to 1 ~~or 2, provided that if m is 2, then n is 1~~;

p is an integer equal to 1 ~~or 2~~;

q is an integer equal to 0 ~~or 1~~;

Q is O ~~or NR^3~~;

X is a covalent bond ~~or a bivalent radical of formula –O–, –S– or –NR^3–~~;

~~each R^3 independently from each other, is hydrogen or alkyl~~;

each R^1 ~~independently from each other,~~ is independently ~~selected from the group of~~ Ar^1[[,]]or Ar^1-alkyl ~~and di(Ar^1) alkyl~~;

R^2 is Ar^2~~, Ar^2-alkyl, di(Ar^2)alkyl, Het^1 or Het^1-alkyl~~;

Y is a covalent bond or a bivalent radical of formula -C(=O)-[[,]]or -SO_2-~~, >C=CH-R or >C=N-R, wherein R is CN or nitro~~;

each Alk is~~represents~~, independently from each other, a covalent bond ; a bivalent straight ~~or branched~~, saturated ~~or unsaturated~~ hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more ~~alkyl,~~ phenyl~~, halo, cyano, hydroxy, formyl and amino~~ radicals ;

L is ~~selected from the group of~~ hydrogen, alkyl, ~~alkyloxy, Ar^3-oxy, alkyloxycarbonyl, alkylcarbonyloxy, mono- and di(alkyl)amino, mono- and di(Ar^3)amino,~~ mono- or ~~and~~ di(alkyloxycarbonyl)amino, Ar^3, ~~Ar^3carbonyl,~~ or

Het^2 ~~and Het^2carbonyl~~ ;

Ar^1 is phenyl~~, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy~~ ;

Ar^2 is ~~naphtalenyl or~~ phenyl, ~~each~~ optionally substituted with 1, 2 or 3 alkyl substituents~~, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl~~ ;

Ar^3 is ~~naphthalenyl or~~ phenyl, optionally substituted with 1[[,]] or 2 ~~or 3~~ substituents, each independently ~~from each other, selected from the group of alkyloxy, alkyl,~~ halo~~, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and~~ or cyano ;

~~Het^1 is a monocyclic heterocyclic radical selected from the the group of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl ; or a bicyclic heterocyclic radical selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl ; each heterocyclic radical may optionally be substituted on any atom by a radical selected from the group of halo and alkyl ;~~

Het^2 is a monocyclic heterocyclic radical that is ~~selected from the group of~~ pyrrolidinyl~~, dioxolyl, imidazolidinyl, pyrrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl,~~ tetrahydrofuranyl, ~~2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrrazolinyl, pyrrolyl, imidazolyl,~~ pyrazolyl, ~~triazolyl,~~ furanyl, thienyl, ~~oxazolyl, isoxazolyl, thiazolyl,~~ thiadiazolyl, ~~isothiazolyl,~~ pyridinyl[[,]] or pyrimidinyl~~, pyrazinyl, pyridazinyl and triazinyl ; or a bicyclic heterocyclic radical selected from the group of benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromenyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl ;~~

each radical optionally substituted with one or more alkyl or alkyloxycarbonyl radicals ~~selected from the group of Ar^1, Ar^1alkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkyloxyalkyl and alkyloxycarbonyl~~; and

alkyl is a straight ~~or branched~~ saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ~~; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino~~.

2. (Cancelled) ~~A compound according to claim 1, characterized in that~~

~~n is 1 ;~~
~~m is 1 ;~~
~~p is 1 ;~~
~~q is 0 ;~~
~~Q is O ;~~
~~X is a covalent bond ;~~
~~each R^1 is Ar^1 or Ar^1-alkyl ;~~
~~R^2 is Ar^2 ;~~
~~Y is a covalent bond or a bivalent radical of formula -C(=O)- or $-SO_2-$;~~
~~each Alk represents, independently from each other, a covalent bond ; a bivalent straight saturated hydrocarbon radical having from 1 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl radicals ;~~
~~L is selected from the group of hydrogen, alkyl, mono- and di(alkyloxycarbonyl)amino, Ar^3 and Het^2 ;~~
~~Ar^1 is phenyl ;~~
~~Ar^2 is phenyl, each optionally substituted with 1,2 or 3 alkyl substituents ;~~
~~Ar^3 is phenyl, optionally substituted with 1 or 2 substituents, each independently from each other selected from the group of halo and cyano ;~~
~~Het^2 is a monocyclic heterocyclic radical selected from the group of tetrahydrofuranyl, pyrrolidinyl, pyrazolyl, furanyl, thienyl, pyrimidinyl, thiadiazolyl and pyridinyl ; each radical optionally substituted with one or more alkyl or alkyloxycarbonyl radicals ; and~~
~~alkyl is a straight saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms.~~

3. (Previously Presented) A compound according to claim 1 wherein R^1 is Ar^1methyl and attached to the 2-position or R^1 is Ar^1 and attached to the 3-position.

4. (Previously Presented) A compound according to claim 1 wherein the R^2-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Canceled) ~~A compound according to claim 1 wherein p is 1.~~

6. (Previously Presented) A compound according to claim 1 wherein Y is -C(=O)-.

7. (Previously Presented) A compound according to claim 1 wherein Alk is a covalent bond.

8. (Previously Presented) A compound according to claim 1 wherein L is Het^2.

9. (Currently Amended) A compound that is ~~selected from the group of compounds with compound number 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22 as described in Table 1.~~

(2R-trans) [4-(4-azetidin-3-yl-piperazin-1-yl)-2-benzyl-piperidin-1-yl]-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans){4-[4-(1-benzoyl-azetidin-3-yl)-piperazin-1-yl]-2-benzyl-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans)3-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidine-1-carbonyl)-benzonitrile;

(2R-trans) (2-benzyl-4-{4-[1-(3,4-difluoro-benzoyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(pyridine-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(2,5-dimethyl-*2H*-pyrazole-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(thiophene-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(furan-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) {2-benzyl-4-[4-(1-cyclopropanecarbonyl-azetidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-((*3R*) tetrahydro-furan-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-((*3S*) tetrahydro-furan-3-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) [2-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidin-1-yl)-1,1-dimethyl-2-oxo-ethyl]-carbamic acid *tert*-butyl ester;

(2R-trans) 1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidin-1-yl)-2-phenyl-propan-1-one;

(2R-trans) (2-benzyl-4-{4-[1-(thiophene-2-sulfonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans)1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidin-1-yl)-2,2-dimethyl-propan-1-one;

(2R-trans) (2-benzyl-4-{4-[1-(2-chloro-benzoyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) {2-benzyl-4-[4-(1-pyrazin-2-yl-azetidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) (2-benzyl-4-{4-[1-(pyrazine-2-carbonyl)-azetidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone;

(2R-trans) 2-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidine-1-carbonyl)- (*2R*) pyrrolidine-1-carboxylic acid *tert*-butyl ester; or

(2R-trans) 2-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-azetidine-1-carbonyl)- (*2S*) pyrrolidine-1-carboxylic acid *tert*-butyl ester.

10. (Canceled)

11. (Canceled)

12. (Currently Amended) A method for treating a patient suffering from ~~The use of a compound according to claim 1 for treating~~ schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain, neurogenic

inflammation, asthma, micturition disorders or ~~and~~ nociception, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1.

13. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

14. (Previously Presented) A process for preparing a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound of claim 1.

15. (Currently Amended) A process for the preparation of a compound of Formula (I") in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III)~~, wherein the radicals R^2, X, Q, R^1, m, n, p and q are as defined in claim 1.~~



(II) (III) (I")

wherein

X is a covalent bond;

each R^1 is independently Ar^1 or Ar^1-alkyl;

R^2 is Ar^2;

n is an integer, equal to 1;

m is an integer, equal to 1;

p is an integer equal to 1;

q is an integer equal to 0; and

Q is O.

16. (Original) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I'') is reductively hydrogenated~~, wherein the radicals R^2, X, Q, R^1, m, n, p and q are as defined in claim 1.~~



(I'') (I')

wherein

X is a covalent bond;

each R^1 is independently Ar^1 or Ar^1-alkyl;

R^2 is Ar^2;

n is an integer, equal to 1;

m is an integer, equal to 1;

p is an integer equal to 1;

q is an integer equal to 0; and

Q is O.

17. (Original) A process for the preparation of a compound according to Formula (I') comprising the consecutive steps of

1) obtaining a compound of Formula (I'') according to claim 15 ;

2) obtaining a compound of Formula (I') according to claim 16